In target safety assessments, MR analyses found that increased ADGRF5 levels were suggestively associated with an increased risk of ovarian cancer (p‐value of inverse variance‐weighted method = 0.047) and breast cancer (p‐value of inverse variance‐weighted method = 0.042). Here, ADGRF5 is linked to ovarian carcinoma.